The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s gastric cancer drugs market report forecasts the gastric cancer drugs market size to grow to $5.03 Billion by 2027, with a CAGR (compound annual growth rate) of more than 10%.

Learn More On The Gastric Cancer Drugs Market Report 2023 – https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastric Cancer Drugs Market Size Forecast
The global gastric cancer drugs market is expected to grow from $3.02 billion in 2022 to $3.38 billion in 2023 at a compound annual growth rate (CAGR) of 11.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global gastric cancer drugs market size is expected to grow to $5.03 billion in 2027 at a CAGR of 10.5%.

North America held the largest gastric cancer drugs market share, and Middle East was the fastest-growing region in 2022.

Key Gastric Cancer Drugs Market Driver ­– Increase In Several Cases Of Gastric Cancer
According to the estimates of the American Institute for Cancer Research for 2020, about 27,600 cases of stomach cancer will be diagnosed (16,980 in men and 10,620 in women). An increase in several cases of gastric cancer will drive the market for gastric cancer drugs.

Request for A Sample Of The Global Gastric Cancer Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

Key Gastric Cancer Drugs Market Trend – Adopting Combination Therapies
Many companies are using combination therapies to cure gastric cancer. Combination therapies improve patient care by treating patients with two or more drugs for a single disease. For instance, in January 2021, AstraZeneca PLC., a UK-based pharmaceutical and biotechnology company, announced that for the treatment of adult patients with locally progressed or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinomas who have previously undergone a trastuzumab-based regimen, Enhertu (trastuzumab deruxtecan) has been approved in the US by the Food and Drug Administration (FDA). This trastuzumab plus a fluoropyrimidine- and platinum-based chemotherapy combination is administered to patients suffering from advanced gastric cancer or GEJ adenocarcinoma.

Gastric Cancer Drugs Market Segment
1) By Type: Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab
2) By End User: Hospitals, Clinics, Other End-users
3) By Route of Administration: Oral, Parenteral

Gastric Cancer Drugs Market Major Players and Strategies
Major players in the gastric cancer drugs market are Eli Lilly and company, Novartis, Merck KGaA, Otsuka Pharmaceutical, F. Hoffmann-La Roche, GlaxoSmithKline PLC., Bristol-Myers Squibb, Sanofi, Pfizer Inc., AstraZeneca, Bayer Healthcare, Abbott, AROG Pharmaceuticals, Ipsen Biopharmaceuticals, Array Biopharma, Taiho Oncology, AstraZeneca, ARIAD Pharmaceuticals, Ono Pharmaceutical, Jiangsu HengRui Medicine, Gilead Bioscience, Celgene/Taiho, Boston Biomedical, Imugene Limited, Boehringer Ingelheim, Daiichi-Sankyo, Danaher corporation.

In March 2021, Amgen Inc., a US-based biopharmaceutical company specialising in the discovery, development, manufacturing, and commercialization of drugs and novel therapeutics, acquired Five Prime Therapeutics, Inc. for an amount of $1.9 billion. Through this acquisition, Amgen increases its oncology product portfolio, gastric cancer treatment assets, monoclonal antibody manufacturing capabilities, and drug development capabilities, including those for biological drugs for the treatment of advanced gastric or gastroesophageal junction (GEJ) cancer. Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company pioneering in the discovery and development of immuno-oncology protein therapeutics for cancer treatment.

The Gastric Cancer Drugs Global Market Report 2023 covers regional data on gastric cancer drugs market size, gastric cancer drugs market trends and drivers, opportunities, strategies, and gastric cancer drugs market competitor analysis. The countries covered in the gastric cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Gastric cancer drugs refer to anti-cancer medications that are taken orally as pills or are injected into a vein (via an IV line or central venous catheter). This treatment is effective for cancer that has spread to organs other than those where it originated since these medications penetrate the bloodstream and reach every part of the body.

View More Reports Related To The Gastric Cancer Drugs Market –
Cancer Biologics Global Market Report 2023
Cancer Monoclonal Antibodies Global Market Report 2023
Cancer Clinical Decision Tools Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: